Glenmark Life Sciences Limited(IN:ALIVUS)
₹1,434.15-15.70 (-1.08%)
IN:ALIVUS
Glenmark Life Sciences Limited financials statements
₹1,434.15
At close:-15.70 (-1.08%)
Want to see IN:ALIVUS full AI Analyst Report?
Glenmark Life Sciences Limited (ALIVUS) Financial Statements
6 Followers
Glenmark Life Sciences Limited Financial Overview
Glenmark Life Sciences Limited's market cap is currently ₹176.35B. The company's EPS TTM is ₹20.67; its P/E ratio is 26.34; and it has a dividend yield of 0.35%. Glenmark Life Sciences Limited has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 25 | Mar 24 | Mar 22 | Mar 21 | Mar 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | ₹ 25.52B | ₹ 22.83B | ₹ 21.61B | ₹ 18.85B | ₹ 15.37B |
| Gross Profit | ₹ 11.37B | ₹ 12.43B | ₹ 11.47B | ₹ 9.80B | ₹ 8.47B |
| Operating Income | ₹ 7.22B | ₹ 8.98B | ₹ 6.01B | ₹ 5.62B | ₹ 4.44B |
| EBITDA | ₹ 8.32B | ₹ 6.86B | ₹ 6.71B | ₹ 5.92B | ₹ 4.84B |
| Net Income | ₹ 5.64B | ₹ 4.71B | ₹ 4.67B | ₹ 3.52B | ₹ 3.13B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | ₹ 7.83B | ₹ 3.01B | ₹ 3.80B | ₹ 1.40B | ₹ 307.68M |
| Total Assets | ₹ 39.83B | ₹ 28.50B | ₹ 27.02B | ₹ 19.97B | ₹ 17.26B |
| Total Debt | ₹ 567.71M | ₹ 171.48M | ₹ 193.57M | ₹ 9.33B | ₹ 210.00K |
| Net Debt | ₹ 546.39M | ₹ -2.84B | ₹ -2.64B | ₹ 8.17B | ₹ -99.77M |
| Total Liabilities | ₹ 6.51B | ₹ 5.18B | ₹ 5.64B | ₹ 12.44B | ₹ 13.24B |
| Stockholders' Equity | ₹ 33.32B | ₹ 23.32B | ₹ 21.38B | ₹ 7.53B | ₹ 4.02B |
| Cash Flow | |||||
| Free Cash Flow | ₹ 2.59B | ₹ 2.85B | ₹ 1.43B | ₹ 3.20B | ₹ 1.44B |
| Operating Cash Flow | ₹ 5.66B | ₹ 4.14B | ₹ 3.13B | ₹ 3.88B | ₹ 1.95B |
| Investing Cash Flow | ₹ -5.71B | ₹ -1.16B | ₹ -1.54B | ₹ -687.34M | ₹ -505.18M |
| Financing Cash Flow | ₹ -641.34M | ₹ -2.79B | ₹ -3.88B | ₹ -2.14B | ₹ -1.37B |
Currency in INR
